Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Tournai – page 71

1 811 clinical trials in Tournai, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tournai at a glance
1 811
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 811 trials in Tournai

Open in trial search

Graft versus host disease

Not yet recruiting

Safety and Efficacy of MaaT013 with Vancomycin in Children and Adolescents with Gastrointestinal Acute Graft‑versus‑Host Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Vancomycin
  • Sponsor:Maat Pharma

B-cell lymphoma+1

Not yet recruiting

Comparing human normal immunoglobulin (iv) and a drug combination to prevent infections in adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma treated with CAR-T cells

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Plasma cell myeloma

Not yet recruiting

A study of belantamab mafodotin and mezigdomide in patients with relapsed multiple myeloma who have previously received CAR-T cell therapy or bispecific antibodies

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

A study of mezigdomide, carfilzomib, and dexamethasone in patients with relapsed or refractory multiple myeloma.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Assistance Publique Hopitaux De Paris

Axial spondyloarthritis

Not yet recruiting

A study comparing bimekizumab and adalimumab for treating chest pain in patients with active axial spondyloarthritis who do not respond well to non-steroidal anti-inflammatory drugs.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire Rouen

Bacterial vaginosis

Not yet recruiting

Using a drug combination to treat vaginal flora abnormalities in pregnant women at high risk of preterm birth.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ceftriaxone
  • Sponsor:Assistance Publique Hopitaux De Marseille

Acute lymphocytic leukaemia+1

Not yet recruiting

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Amgen Inc.

Ischaemic stroke

Not yet recruiting

Comparing tenecteplase and mechanical clot removal versus mechanical clot removal alone for adults with a large ischemic stroke

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Assistance Publique Hopitaux De Paris

Post procedural complication+3

Not yet recruiting

Study of lidocaine hydrochloride to reduce side effects from pain medication in patients undergoing open liver surgery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Study of the effect of metyrapone in patients with mild Cushing syndrome caused by primary bilateral macronodular adrenal hyperplasia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Metyrapone
  • Sponsor:Assistance Publique Hopitaux De Paris

Plasma cell myeloma

Not yet recruiting

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Hospices Civils De Lyon

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Tournai

What the registry says about research in the country

01 Inflammatory Bowel Disease Research

Comprehensive studies focusing on Crohn's disease and ulcerative colitis treatments, evaluating new therapeutic approaches for patients with moderate to severe conditions.

  • Novel therapeutic agents evaluation
  • Post-operative disease management
  • Long-term treatment effectiveness

Multiple trials are investigating innovative medications including obefazimod and mirikizumab for improved patient outcomes.

02 Gastrointestinal Disorders

Groundbreaking research into eosinophilic esophagitis treatment options, examining the efficacy of new medications for reducing inflammation and improving symptoms.

  • Tissue inflammation reduction
  • Dysphagia symptom management
  • Long-term safety studies

Current trials are evaluating solrikitug as a potential treatment option for patients with EoE.

03 Oncology Studies

Advanced research in breast cancer treatment, particularly focusing on HER2-negative and estrogen receptor-positive cases in elderly patients.

  • Genomic-guided therapy
  • Adjuvant treatment optimization
  • HPV infection management

Studies are exploring personalized treatment approaches combining chemotherapy and hormone therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.